First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

埃罗替尼 医学 肿瘤科 内科学 表皮生长因子受体 肺癌 盐酸厄洛替尼 临床终点 T790米 无进展生存期 癌症 进行性疾病 临床试验 化疗 吉非替尼
作者
Keunchil Park,Chong‐Jen Yu,Sang-We Kim,Meng-Chih Lin,Virote Sriuranpong,Chun-Ming Tsai,Jong-Seok Lee,Jin Hyoung Kang,K.C. Chan,Pablo Ernesto Pérez,Peter Button,Myung‐Ju Ahn,Tony Mok
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:2 (3): 305-305 被引量:217
标识
DOI:10.1001/jamaoncol.2015.4921
摘要

Continuing molecularly targeted treatment beyond disease progression in non-small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses, highlighting the challenge to identify whether progression is the optimal time to switch treatment.To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy.ASPIRATION (Asian Pacific trial of Tarceva as first-line in EGFR mutation) was a phase 2, open-label, single-arm study conducted from 2011 to 2012 in 23 centers in Hong Kong, Korea, Taiwan, and Thailand of adults with stage IV, EGFR mutation-positive NSCLC, with ECOG performance status 0 to 2.Patients received erlotinib 150 mg/d orally until disease progression, after which erlotinib therapy could be continued at patient and/or investigator discretion.The primary end point was progression-free survival (PFS1; time to Response Evaluation Criteria in Solid Tumours 1.1 progression or death). Secondary end points included PFS2 (time to off-erlotinib progression if erlotinib therapy was extended beyond progression at patient and/or investigator discretion), objective response rate, disease control rate, overall survival, and safety. The use of plasma-based assessment of EGFR mutations was also investigated.Of 359 patients screened, 208 were enrolled. Median follow-up was 11.3 (95% CI, 10.9-13.0) months. Of the 207 intent-to-treat patients (62.3% female; median age, 60.8 [range, 28-89] y), 176 had a PFS1 event (171 progression and 5 deaths); of these, 78 discontinued and 93 continued erlotinib therapy following progression. Median PFS1 was 10.8 (95% CI, 9.2-11.1) months. Median PFS1 and PFS2 in the 93 continuing patients was 11.0 (95% CI, 9.2-11.1) and 14.1 (95% CI, 12.2-15.9) months, respectively. Median PFS1 and PFS2 was 11.0 (95% CI, 9.3-12.0) and 14.9 (95% CI, 12.2-17.2) months in patients with exon 19 deletions or L585R mutations. Overall response rate was 66.2%; disease control rate was 82.6%. Median overall survival was 31.0 months (95% CI, 27.3 months to not reached). In the safety population (n = 207) serious adverse events were reported in 27.1%, with events of at least grade 3 experienced by 50.2%. Sensitivity and specificity of plasma-based EGFR mutation analysis was 77% and 92%, respectively.ASPIRATION supports the efficacy of first-line erlotinib therapy in patients with EGFR mutation-positive NSCLC and that treatment beyond progression is feasible and may delay salvage therapy in selected patients.clinicaltrials.gov Identifier: NCT01310036.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
dongdong完成签到 ,获得积分10
1秒前
别闹闹完成签到 ,获得积分10
3秒前
炙热的笑翠完成签到,获得积分10
5秒前
可露丽完成签到,获得积分10
5秒前
dingdingding完成签到,获得积分10
5秒前
CyrusSo524完成签到,获得积分10
6秒前
独特的谷雪完成签到,获得积分10
6秒前
海风吹发布了新的文献求助10
6秒前
czx完成签到,获得积分10
6秒前
赟yun完成签到,获得积分0
7秒前
halalalaa完成签到,获得积分10
8秒前
lee完成签到 ,获得积分10
12秒前
SciKid524完成签到 ,获得积分10
12秒前
木偶完成签到 ,获得积分10
14秒前
开心向真完成签到,获得积分10
14秒前
Lucas应助斑马采纳,获得10
14秒前
Ho完成签到,获得积分10
15秒前
Mr_I完成签到,获得积分10
15秒前
ljx完成签到 ,获得积分10
15秒前
16秒前
ccx完成签到,获得积分10
19秒前
海风吹发布了新的文献求助10
19秒前
Fe2O3完成签到,获得积分10
22秒前
谦让汝燕完成签到,获得积分10
23秒前
25秒前
範範完成签到,获得积分10
25秒前
tongkaibing完成签到,获得积分10
26秒前
米斯特刘完成签到,获得积分10
26秒前
黑眼圈完成签到 ,获得积分10
29秒前
29秒前
无私的雪瑶完成签到 ,获得积分10
29秒前
30秒前
小马哥完成签到,获得积分10
31秒前
海风吹发布了新的文献求助10
32秒前
痴情的靖柔完成签到 ,获得积分10
33秒前
Killua完成签到,获得积分10
33秒前
现代完成签到,获得积分10
35秒前
qq完成签到,获得积分10
37秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
Problems of point-blast theory 400
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4001511
求助须知:如何正确求助?哪些是违规求助? 3540922
关于积分的说明 11278823
捐赠科研通 3278733
什么是DOI,文献DOI怎么找? 1808181
邀请新用户注册赠送积分活动 884376
科研通“疑难数据库(出版商)”最低求助积分说明 810291